- 論 文
- Miyaji T, Kawaguchi T, Kimura T, Mercieca-Bebber R and Yamaguchi T. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols – The SPIRIT-PRO extension –. Jpn Pharmacol Ther 2020 48（10）1697-712. (Translation)
- Kawaguchi T, Miyaji T, Kimura T, Mercieca-Bebber R and Yamaguchi T.Reporting of Patient-Reported Outcomes in Randomized Trials ─ The CONSORT PRO Extension ─. Jpn Pharmacol Ther 2020 48（11）1863-74. (Translation)
- 宮路天平. これからの臨床研究のデータ収集方法とデザイン. シンポジウム1 ●これからの臨床研究（GCP renovation を踏まえて）. 日本臨床試験学会 第11回学術集会. Jpn Pharmacol Ther 2020; 48(s2): s74-76.
- 宮路天平. データマネジメント—現状と課題—. シンポジウム3 ●世界と未来のデータサイエンス. 日本臨床試験学会 第11回学術集会. Jpn Pharmacol Ther 2020; 48(s2): s90-92.
- 宮路天平, 川口崇, 山口拓洋. ePROと電子カルテ ～その連携と活用～. がん看護 2020; 25(7):636-8.
- 川口崇, 宮路天平, 山口拓洋. SPIRIT-PRO 看護研究. 2020 53(2): 134-5.
- 山口拓洋, 川口崇, 宮路天平. がん領域におけるePRO: electronic Patient Reported Outcome(ePRO)in Oncology. CANCER BOARD of the BREAST. 2020:6(1).
- Miyaji T, Kawaguchi T, Azuma K. et al. Patient-generated health data collection using a wearable activity tracker in cancer patients—a feasibility study. Support Care Cancer (2020).
- Matsuoka H, Iwase S, Miyaji T, et al. Predictors of duloxetine response in patients with neuropathic cancer pain: A secondary analysis of a randomized controlled trial—JORTC-PAL08 (DIRECT) study. Supportive Care in Cancer (2019). https://doi.org/10.1007/s00520-019-05138-9
- Matsuoka H, Iwase S, Miyaji T, et al. Additive Duloxetine for Cancer-related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08). J Pain Symptom Manage. 2019 Oct;58(4).
- Matsuda Y, Morita T, Miyaji T, Ogawa T, Kato K, Kawaguchi T, Tokoro A, Iwase S, Yamaguchi T, Inoue Y. Morphine for Refractory Dyspnea in Interstitial Lung Disease: A Phase I Study (JORTC-PAL 05). Journal of Palliative Medicine. J Palliat Med. 2018 Aug 21. doi: 10.1089/jpm.2018.0272.
- Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, and Kitayama J, for the Japan Intraperitoneal Chemotherapy Study Group. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Gastric Cancer Patients with Peritoneal Metastasis: PHOENIX-GC Trial. J Clin Oncol May 10 2018
- Kawaguchi T, Azuma K, Sano M, Kim S, Kawahara Y, Sano Y, Shimodaira T, Ishibashi K, Miyaji T, Basch E, Yamaguchi T. The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): The psychometric validation and discordance between clinician and patient assessments of adverse events. Journal of Patient-Reported Outcomes. 2018;2:2.
- Miyaji T, Iioka Y, Kuroda Y, Yamamoto D, Iwase S, Goto Y, Tsuboi M, Odagiri H, Tsubota Y, Kawaguchi T, Sakata N, Basch E, Yamaguchi T. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Journal of Patient-Reported Outcomes. 2017;1:8.
- Tantsyura V, Mitchel J, Kim YJ, Miyaji T, Yamaguchi T, McCanless Dunn. Risk-Based Approaches to Data Management and Data Quality: Double Standards or Is It Just Common Sense and Intelligence Taking Over?. Data Basics. 2017; 23: 1
- Miyaji T, Nagasawa M, Yamaguchi T, Tsutani K. Tackling the Pharmaceutical Frontier: Regulation of cannabinoid-based medicines in postwar Japan. Cannabis Cannabinoid Res. January 2016, 1(1): 31-37.
- Iwase S, Yamaguchi T, Miyaji T, et al. The clinical use of Kampo medicines (traditional Japanese herbal treatments) for controlling cancer patients' symptoms in Japan: a national cross-sectional survey. BMC Complement Altern Med. 2012 Nov 20;12:222.
- 受 賞
- 若手研究者奨励賞. 第20回統合医療機能性食品国際会議(2012).
|
